Áreas terapeúticas

TZIELD is the first and only immunomodulator indicated to delay the onset of Stage 3 T1D in patients aged 8 years and older with Stage 2 T1D. In the TN-10 study, one 2-week course of TZIELD doubled the median time to Stage 3 onset compared to placebo⁵. The median follow-up time was 51 months. In the extended follow-up of the TN-10 study, the median time to Stage 3 onset was approximately 5 years with TZIELD versus approximately 2 years with placebo⁶. Choose proactive intervention, Treat appropriate stage 2 T1D patients with TZIELD today.

¿Por qué es importante adelantarse a reducir los niveles de colesterol de los pacientes? Descúbralo aquí.

¿Debe mantener bajo el nivel de colesterol del paciente?​

¿Los niveles de colesterol deben realmente estar bajos? ¿Cuánto tiempo deben permanecer así? Descúbralo en esta lista de reproducción.

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2